BIOQUAL was established in 1981, and performs contract research services focused on in vivo models of human diseases including AIDS, influenza, RSV infection, Flavivirus infections including Zika and Dengue, malaria, hepatitis, and cancer. BIOQUAL has laboratories and vivariums under both BSL-2 and BSL-3 containment. In addition, BIOQUAL maintains CDC-approved BSL-3 containment laboratories for studies associated with Select Agents including highly pathogenic avian influenza.
BIOQUAL’s laboratories are actively involved in the evaluation of vaccines, vaccine therapeutics, microbicides, and drug therapies. In vitro services are available for evaluation of immunologic, virologic, and molecular parameters. These services include sample processing, virus stock generation, quantitation of infectious virus, virus neutralization assays, hemagglutination inhibition assay, quantitative PCR, antigen and antibody ELISA detection assays, flow cytometry, lymphocyte proliferation, and other cell-based assays.